BIOMAT Database Logo BIOMAT Database Logo

Serum immunoactive inhibin levels in early pregnancy after in vitro fertilization and embryo transfer. 1993

T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Monash University, Prince Henry's Institute of Medical Research, Monash Medical Centre, Melbourne, Victoria, Australia.

OBJECTIVE To determine the maternal serum concentrations of inhibin, E2, P, and hCG in early pregnancies arising from IVF and ET or GIFT and to assess the value of these hormone measurements in determining outcome of pregnancy. METHODS Serum immunoactive inhibin, E2, P, and hCG levels were measured in the first trimester of pregnancies after IVF-ET and GIFT procedures. METHODS In vitro fertilization and ET or GIFT was undertaken at Monash IVF, Melbourne, Victoria, Australia. METHODS At least two blood samples were collected from 117 women between 4 and 11 weeks of gestation. METHODS The hormone concentrations in the IVF-ET and GIFT pregnancies were compared with those in pregnancies and related to outcome of pregnancy. RESULTS Serum inhibin levels in singleton pregnancies were significantly higher than in comparable normal pregnancies. In contrast to normal conceptions in which inhibin concentrations rose to peak at 11 weeks, the levels found in IVF-ET and GIFT singleton pregnancies were high at 5 weeks' gestation and declined subsequently. In twin pregnancies, the inhibin levels were significantly greater than those in singleton pregnancies. In biochemical pregnancies diagnosed by increasing hCG concentrations in the absence of an embryonic sac, inhibin levels were significantly lower than those found in singleton pregnancy, as were E2, P, and hCG levels. In anembryonic pregnancies, diagnosed by the confirmation of an intrauterine gestation sac with no evidence of a fetal complex, inhibin concentrations were highest at week 4 and declined, being significantly lower at all stages of gestation. In ectopic pregnancy, serum inhibin levels were lower at all stages of gestation, whereas E2 concentrations were not lower until 6 weeks and P levels until week 5. Serum hCG levels were significantly lower at all stages of gestation. In women with spontaneous abortions, inhibin levels were lower than singleton pregnancies at 7 weeks. CONCLUSIONS Serum inhibin concentrations are elevated in pregnancies arising from ovarian hyperstimulation in the first trimester when compared with those in normal pregnancy, probably as a result of the presence of multiple corpora lutea resulting from ovarian hyperstimulation. Serum inhibin, E2, P, and hCG are useful markers of abnormal pregnancy outcome.

UI MeSH Term Description Entries
D007265 Inhibins Glycoproteins that inhibit pituitary FOLLICLE STIMULATING HORMONE secretion. Inhibins are secreted by the Sertoli cells of the testes, the granulosa cells of the ovarian follicles, the placenta, and other tissues. Inhibins and ACTIVINS are modulators of FOLLICLE STIMULATING HORMONE secretions; both groups belong to the TGF-beta superfamily, as the TRANSFORMING GROWTH FACTOR BETA. Inhibins consist of a disulfide-linked heterodimer with a unique alpha linked to either a beta A or a beta B subunit to form inhibin A or inhibin B, respectively Female Inhibin,Inhibin,Inhibin-F,Inhibins, Female,Inhibins, Testicular,Ovarian Inhibin,Testicular Inhibin,Female Inhibins,Inhibin F,Inhibin, Female,Inhibin, Ovarian,Inhibin, Testicular,Testicular Inhibins
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011271 Pregnancy, Ectopic A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (>96%) occur in the FALLOPIAN TUBES, known as TUBAL PREGNANCY. They can be in other locations, such as UTERINE CERVIX; OVARY; and abdominal cavity (PREGNANCY, ABDOMINAL). Ectopic Pregnancy,Pregnancy, Extrauterine,Ectopic Pregnancies,Extrauterine Pregnancies,Extrauterine Pregnancy,Pregnancies, Ectopic,Pregnancies, Extrauterine
D011272 Pregnancy, Multiple The condition of carrying two or more FETUSES simultaneously. Multiple Pregnancy,Multiple Pregnancies,Pregnancies, Multiple
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D004624 Embryo Transfer The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO. Blastocyst Transfer,Tubal Embryo Transfer,Tubal Embryo Stage Transfer,Embryo Transfers,Transfer, Embryo,Transfers, Embryo
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females

Related Publications

T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Inhibin A level in early pregnancy following in-vitro fertilization and embryo transfer.
July 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Early primary abdominal pregnancy after in vitro fertilization and embryo transfer.
May 1993, Journal of assisted reproduction and genetics,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
[Pregnancy after fertilization in vitro and embryo transfer].
January 1985, Jugoslavenska ginekologija i perinatologija,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Heterotopic pregnancy after in vitro fertilization-embryo transfer.
September 2004, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Abdominal pregnancy after in vitro fertilization and embryo transfer.
September 1988, Obstetrics and gynecology,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Cervical pregnancy after in vitro fertilization and embryo transfer.
November 1989, American journal of obstetrics and gynecology,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Intramural pregnancy after in vitro fertilization and embryo transfer.
January 1992, Fertility and sterility,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Heterotopic pregnancy after in vitro fertilization and embryo transfer.
April 1998, Acta obstetricia et gynecologica Scandinavica,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Pregnancy after in vitro fertilization, cryopreservation, and embryo transfer.
August 1986, Journal of in vitro fertilization and embryo transfer : IVF,
T Yohkaichiya, and D W Polson, and E G Hughes, and V MacLachlan, and D M Robertson, and D L Healy, and D M de Kretser
Heterotopic pregnancy after in vitro fertilization and embryo transfer.
May 1986, Fertility and sterility,
Copied contents to your clipboard!